BIOLOG-ID
Biolog-id, a global service provider of connected healthcare solutions, and Inlog , a software company dedicated to the medical sector, have announced today a strategic interoperability partnership for their solutions.
With a market presence of more than 30 years, Inlog has developed software suites that ensure the quality and the traceability of products throughout the transfusion supply chain. These software suites are used today by nearly 250 French and international clients, including an important part of University Hospitals.
To allow blood centers and hospitals to take advantage of the RFID technology, Inlog and biolog-id are partnering to guarantee the interoperability of the Edge Track (Hemo Server) and Edge Blood (CTS Server) software with the Biolog Data System modules from the Biolog Transfusion Solution.
By combining RFID tags containing essential information of blood products, connected equipment, and a dedicated transactional and decision-making software, Biolog Transfusion Solution secures the entire blood transfusion supply chain, from the donor to the recipient. Beyond reinforcing the safety of transfused patients, the solution optimizes in real-time the local and remote inventory management of these vital therapeutic products and allows them to be attributed nominatively remotely and safely.
“We are very pleased that Inlog, who is today a reference in the field of blood supply chain management, and biolog-id collaborate to propose their users and prospects an option for strengthening traceability and securing the transfusion chain based on our RFID solution”, says Bruno Chappert, CEO at biolog-id. “This interoperability agreement will enable us to offer transfusion professionals a new feature capable of improving their efficiency, optimizing working conditions while adapting to all types of structures, and finally facilitating the rapid implementation of these software solutions”.
“We are convinced that this interoperability agreement between biolog-id and Inlog will provide healthcare and transfusion facilities with better blood product management, enhanced safety and improved traceability”, underlines David Kalfon, President at Inlog. “The numerous combined advantages of biolog-id and Inlog solutions will allow the transfusion chain professionals to rationalize their operations and optimize their costs”.
The Inlog software and Biolog Transfusion Solution will be available under different technical models to allow simple, fast and modular integration by healthcare infrastructures and to meet users’ needs.
About biolog-id
:
Biolog-id develops and implements innovative solutions, that digitally transform routine processes into actionable data supporting better operational and strategic decisions for sensitive therapeutic products: blood products (red blood cells, platelets, plasma), chemotherapies, parenteral nutrition.
The information generated by biolog-id solutions is available to Healthcare Professionals at any time, enhancing their processes efficiency, work conditions and ultimately the safety of the therapeutics administered to patients.
Biolog-id’s patented platform is utilized in North America, Europe, Middle East, India, and Asia Pacific. Biolog-id is owned by its founder, managers, and the Xerys Funds. Xerys Gestion is a French investment company primarily positioned on trending sectors that include healthcare & Life Sciences, renewable energy/GreenTech and new digital technologies.
Company URL: www.biolog-id.com
About Inlog:
Founded in 1992, Inlog is one of the leading French software companies in the field of medical informatics for laboratory analysis, traceability of blood products in healthcare facilities and the various activities of blood transfusion centers.
Inlog designs and develops a range of software for the healthcare sector whose advantages in terms of robustness, reliability and ease of configuration are distinguished by all its customers. Motivated by a new management board, Inlog is initiating an ambitious project to use new technologies into its applications to make their use even more ergonomic and intuitive.
The Inlog software suites, CE marked, are used by more than 250 Healthcare institutions in France and around the world (Germany, Switzerland, Belgium, Canada, Hong Kong, etc.), including some prestigious partners such as the Etablissement Français du Sang, the Hôpitaux Universitaires Genevois and the Flemish Red Cross.
Inlog is currently supported by the French investment fund Abénex, a major player in private equity in France.
Company URL: https://www.inlog.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20210706005565/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Bioepis Begins Commercialization of BYOOVIZ®, Biosimilar to Lucentis (Ranibizumab), in Europe2.1.2026 08:00:00 CET | Press release
Samsung Bioepis completes full transfer of commercial rights from Biogen back to Samsung Bioepis for BYOOVIZ®BYOOVIZ becomes the fourth biosimilar directly commercialized by Samsung Bioepis in Europe, following EPYSQLI® (eculizumab), OBODENCE® (denosumab), and XBRYK® (denosumab)Pre-filled syringe (PFS) presentation to become available in Europe in the second quarter of 2026 Samsung Bioepis Co., Ltd. today announced that the company has begun direct commercialization of BYOOVIZ®, a biosimilar to Lucentis1 (ranibizumab), in Europe. Samsung Bioepis has been working to ensure seamless transfer of commercial rights from Biogen back to Samsung Bioepis, and BYOOVIZ will now be available as a Samsung Bioepis brand across multiple European countries. “This is a significant milestone for Samsung Bioepis as the company continues to strengthen its presence in Europe by expanding its portfolio of directly commercialized products. Leveraging the past three years of experience with EPYSQLI (eculizuma
Cessna Citation Ascend Enters Into Service, Redefining Performance and Cabin Experience in the Midsize Business Jet Market31.12.2025 15:00:00 CET | Press release
The Cessna Citation Ascend achieved a major milestone as the first retail customer took delivery of the midsize business jet on Tuesday, December 30, marking the aircraft’s entry into service. Announced in 2023 the aircraft boasts an entirely new cockpit, improved performance and a luxurious flat floor cabin. The Citation Ascend received type certification from the Federal Aviation Administration (FAA) in November 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251231586042/en/ Cessna Citation Ascend enters into service, redefining performance and cabin experience in the midsize business jet market. (Photo credit: Textron Aviation) The Cessna Citation Ascend is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company. “The first Citation Ascend delivery underscores Textron Aviation’s commitment to redefining the midsize segment with an aircraft that blends innovation, efficiency and unmatch
Aster Guardians Global Nursing Award 2026 Worth $250,000 Extends Deadline Till 11th January 202631.12.2025 14:08:00 CET | Press release
Due to an extraordinary global response of over 134,000 registrations from 214 countries, the submission deadline has been extended.Nurses worldwide can submit their nominations via www.asterguardians.com The Aster Guardians Global Nursing Award 2026, an initiative from Aster DM Healthcare – a leading integrated healthcare provider, has announced the extension of its deadline to January 11, 2026. The awards have already received over 134,000 registrations from 214 countries, highlighting its growing global reach and recognition among nurses worldwide. Nurses from around the world can submit their nominations through the dedicated platform at www.asterguardians.com. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251231986766/en/ Aster Guardians Global Nursing Award worth USD 250,000 (Photo: AETOSWire) This year, the prestigious award will be hosted in New Delhi, India, celebrating nursing excellence on a truly global stage. T
Tecnotree Included as a Representative Provider in Gartner® Innovation Insight: AI SOC Agents Accelerate CSP SecOps Transformation31.12.2025 11:59:00 CET | Press release
Tecnotree, a global digital platform and services provider for communications service providers (CSPs), today announced that it has been referenced as a Representative Provider alongside Google, Anthropic, Dropzone AI, DRUID, Palo Alto Networks, and Pegasystems in the Gartner® Innovation Insight: “AI SOC Agents Accelerate CSP SecOps Transformation,” published in December 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251231210303/en/ Tecnotree Included as a Representative Provider in Gartner® Innovation Insight: AI SOC Agents Accelerate CSP SecOps Transformation The Gartner Innovation Insight examines the emerging role of AI-driven Security Operations Centre (SOC) agents in CSP environments, outlining how these agents are used to automate and augment security operations across signalling, core networks, RAN, Open RAN, and roaming domains. The research discusses use cases such as alert triage, investigation support, thr
UAE’s Medcare Treats First International SMA Patient With Revolutionary Intrathecal Gene Therapy30.12.2025 15:15:00 CET | Press release
The newly licensed intrathecal gene therapy expands life-changing treatment options for children and adults affected by SMA Medcare Women & Children Hospital has successfully administered a pioneering intrathecal gene therapy for Spinal Muscular Atrophy (SMA) to Hulus, a three-year-old patient from Turkey. This milestone positions Medcare among the first private healthcare providers worldwide to offer this innovative treatment to an older international patient, overcoming previous age and weight limitations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251230695275/en/ World's first international patient, who received intrathecal gene therapy at Medcare Royal Hospital in Dubai, UAE, along with parents, and the hospital team. (Photo: AETOSWire) SMA is a rare neuromuscular disorder that progressively weakens muscles responsible for movement and breathing. This newly licensed one-time therapy addresses the root genetic cause
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
